We speculate that ERα-activated-DNMT1 pathway dominantly propels the drug-induced global DNA hypermethylation in breast cancer, although the effects of DNMT3a/3b cannot be fully excluded in this experimental system and remains to be tested further. The gene discussed is DNMT1; the disease is breast carcinoma.